



## Clinical trial results:

### A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants With Active Systemic Lupus Erythematosus (SLE)

#### Summary

EudraCT number	2018-004175-12
Trial protocol	BE HU GB CZ RO BG PT DE PL ES IT
Global end of trial date	05 October 2023

#### Results information

Result version number	v1 (current)
This version publication date	14 July 2024
First version publication date	14 July 2024

#### Trial information

##### Trial identification

Sponsor protocol code	B7931028
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03845517
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 April 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	05 October 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of 3 once daily (QD) dose levels of PF-06700841 compared to placebo in participants with active SLE.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 April 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 4
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Czechia: 6
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Hungary: 10
Country: Number of subjects enrolled	Japan: 19
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Spain: 8
Country: Number of subjects enrolled	China: 4
Country: Number of subjects enrolled	Portugal: 1
Country: Number of subjects enrolled	Bulgaria: 25
Country: Number of subjects enrolled	Colombia: 24
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Poland: 25
Country: Number of subjects enrolled	Serbia: 19
Country: Number of subjects enrolled	Romania: 11
Country: Number of subjects enrolled	Taiwan: 17
Country: Number of subjects enrolled	Ukraine: 33
Country: Number of subjects enrolled	United Kingdom: 5

Country: Number of subjects enrolled	Mexico: 51
Country: Number of subjects enrolled	United States: 70
Country: Number of subjects enrolled	Greece: 4
Worldwide total number of subjects	350
EEA total number of subjects	96

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	341
From 65 to 84 years	9
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 350 participants with active SLE were enrolled and randomized in the study.

### Pre-assignment

Screening details:

The study was conducted at approximately 185 sites in the 24 countries from 18 April 2019 to 05 October 2023.

### Period 1

Period 1 title	Treatment Period (TP) (52 Weeks)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Participants were randomised to receive placebo matched to PF-06700841 QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received placebo matched to PF-06700841 QD for 52 weeks.

<b>Arm title</b>	PF-06700841 15 mg
------------------	-------------------

Arm description:

Participants were randomised to receive PF-06700841 15 milligram (mg) tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received PF-06700841 15 mg QD for 52 weeks.

<b>Arm title</b>	PF-06700841 30 mg
------------------	-------------------

Arm description:

Participants were randomised to receive PF-06700841 30 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants received PF-06700841 30 mg QD for 52 weeks.	
<b>Arm title</b>	PF-06700841 45 mg

Arm description:

Participants were randomised to receive PF-06700841 45 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received PF-06700841 45 mg QD for 52 weeks.

<b>Number of subjects in period 1</b>	Placebo	PF-06700841 15 mg	PF-06700841 30 mg
Started	100	50	101
Completed	68	36	78
Not completed	32	14	23
Consent withdrawn by subject	4	6	6
Adverse event, non-fatal	12	7	10
Death	-	-	1
Pregnancy	1	-	-
Non-compliance with study drug	1	-	-
Site Terminated by Sponsor	2	-	-
Unspecified	2	-	-
Lost to follow-up	2	-	1
Lack of efficacy	8	1	3
Physician's decision	-	-	1
Protocol deviation	-	-	1

<b>Number of subjects in period 1</b>	PF-06700841 45 mg
Started	99
Completed	71
Not completed	28
Consent withdrawn by subject	5
Adverse event, non-fatal	17
Death	-

Pregnancy	1
Non-compliance with study drug	-
Site Terminated by Sponsor	-
Unspecified	-
Lost to follow-up	-
Lack of efficacy	4
Physician's decision	-
Protocol deviation	1

## Period 2

Period 2 title	Follow-up Period (FU P) (4 Weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	No
<b>Arm title</b>	Placebo

### Arm description:

Participants were randomised to receive placebo matched to PF-06700841 once daily (QD) for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

### Dosage and administration details:

Participants received placebo matched to PF-06700841 QD for 52 weeks.

<b>Arm title</b>	PF-06700841 15 mg
------------------	-------------------

### Arm description:

Participants were randomised to receive PF-06700841 15 milligram (mg) tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

### Dosage and administration details:

Participants received PF-06700841 15 mg QD for 52 weeks.

<b>Arm title</b>	PF-06700841 30 mg
------------------	-------------------

### Arm description:

Participants were randomised to receive PF-06700841 30 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants received PF-06700841 30 mg QD for 52 weeks.	
<b>Arm title</b>	PF-06700841 45 mg

Arm description:

Participants were randomised to receive PF-06700841 45 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received PF-06700841 45 mg QD for 52 weeks.

<b>Number of subjects in period 2</b>	Placebo	PF-06700841 15 mg	PF-06700841 30 mg
Started	68	36	78
Completed	89	42	89
Not completed	11	8	12
Consent withdrawn by subject	3	5	7
Adverse event, non-fatal	4	2	-
Death	-	-	1
Pregnancy	1	-	-
Study terminated by sponsor	-	-	-
Unspecified	1	-	1
Lost to follow-up	2	1	2
Physician's decision	-	-	1
Protocol deviation	-	-	-
Joined	32	14	23
Continue to follow up	32	14	23

<b>Number of subjects in period 2</b>	PF-06700841 45 mg
Started	71
Completed	92
Not completed	7
Consent withdrawn by subject	1
Adverse event, non-fatal	2

Death	1
Pregnancy	-
Study terminated by sponsor	1
Unspecified	-
Lost to follow-up	-
Physician's decision	1
Protocol deviation	1
Joined	28
Continue to follow up	28



## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants were randomised to receive placebo matched to PF-06700841 QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 15 mg
Reporting group description:	
Participants were randomised to receive PF-06700841 15 milligram (mg) tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 30 mg
Reporting group description:	
Participants were randomised to receive PF-06700841 30 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 45 mg
Reporting group description:	
Participants were randomised to receive PF-06700841 45 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	

Reporting group values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg
Number of subjects	100	50	101
Age categorical			
Units: Participants			
Adults (18-64 years)	100	49	97
From 65-84 years	0	1	4
Age Continuous			
Units: Years			
arithmetic mean	42.5	41.5	42.8
standard deviation	± 9.60	± 11.79	± 12.71
Sex: Female, Male			
Units: Participants			
Female	94	45	97
Male	6	5	4
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	2	0	7
Asian	14	9	11
Black or African American	6	4	6
White	71	31	69
More than one race	2	0	0
Unknown or Not Reported	5	6	8
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	29	17	34
Not Hispanic or Latino	71	32	67
Unknown or Not Reported	0	1	0

Reporting group values	PF-06700841 45 mg	Total	
Number of subjects	99	350	

Age categorical			
Units: Participants			
Adults (18-64 years)	95	341	
From 65-84 years	4	9	
Age Continuous			
Units: Years			
arithmetic mean	41.0		
standard deviation	± 11.47	-	
Sex: Female, Male			
Units: Participants			
Female	91	327	
Male	8	23	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	2	11	
Asian	13	47	
Black or African American	7	23	
White	68	239	
More than one race	0	2	
Unknown or Not Reported	9	28	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	35	115	
Not Hispanic or Latino	62	232	
Unknown or Not Reported	2	3	

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants were randomised to receive placebo matched to PF-06700841 QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 15 mg
Reporting group description: Participants were randomised to receive PF-06700841 15 milligram (mg) tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 30 mg
Reporting group description: Participants were randomised to receive PF-06700841 30 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 45 mg
Reporting group description: Participants were randomised to receive PF-06700841 45 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	Placebo
Reporting group description: Participants were randomised to receive placebo matched to PF-06700841 once daily (QD) for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 15 mg
Reporting group description: Participants were randomised to receive PF-06700841 15 milligram (mg) tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 30 mg
Reporting group description: Participants were randomised to receive PF-06700841 30 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 45 mg
Reporting group description: Participants were randomised to receive PF-06700841 45 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.	

### Primary: Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52

End point title	Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52
End point description: SRI-4 components: SLEDAI-2K, BILAG 2004 and PhGA. Participants were classified as SRI-4 responders, if they met all of criteria compared with baseline: 1) $\geq 4$ point reduction in SLEDAI-2K score; 2) no new BILAG A organ domain score or 2 new BILAG B organ domain scores; 3) no worsening $< 0.3$ point increase in PhGA score. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A [severe] to E [no disease]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 [none] to 3 [severe]; higher score = higher severity). Full analysis set (FAS): all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here "Number of Subjects Analyzed" signifies participants at Week 52 with Non-Responder Imputation (NRI) and Last Observation Carried Forward from Week 48 (LOCF48) applied.	
End point type	Primary
End point timeframe: Week 52	

<b>End point values</b>	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	96	47	99	92
Units: Percentage of participants				
number (confidence interval 95%)	64.6 (54.5 to 74.7)	57.4 (42.2 to 72.6)	69.7 (60.1 to 79.3)	66.3 (56.1 to 76.5)

## Statistical analyses

<b>Statistical analysis title</b>	Placebo versus PF-06700841 15 mg
Comparison groups	Placebo v PF-06700841 15 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.8076 <sup>[1]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	-7.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.5
upper limit	9.5

Notes:

[1] - One sided p-value.

<b>Statistical analysis title</b>	Placebo versus PF-06700841 45 mg
Comparison groups	PF-06700841 45 mg v Placebo
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.401 <sup>[2]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.8
upper limit	15.3

Notes:

[2] - One sided p-value.

<b>Statistical analysis title</b>	Placebo versus PF-06700841 30 mg
-----------------------------------	----------------------------------

Comparison groups	PF-06700841 30 mg v Placebo
Number of subjects included in analysis	195
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.2189 <sup>[3]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.9
upper limit	18.3

Notes:

[3] - One sided p-value.

## Secondary: Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52

End point title	Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52
-----------------	---

End point description:

BICLA included: BILAG-2004, SLEDAI-2K and PhGA. Participants were classified as responders, if they met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =<1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (<10 percent [%] worsening) in analogue PhGA. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A [severe] to E [no disease]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 [none] to 3 [severe]; higher score = higher severity). FAS was included. Here "Number of Subjects Analyzed" signifies participants at Week 52 with NRI and LOCF48 applied.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 52

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	96	47	99	92
Units: Percentage of participants				
number (confidence interval 95%)	43.8 (33.3 to 54.2)	42.6 (27.4 to 57.8)	52.5 (42.2 to 62.9)	53.3 (42.5 to 64.0)

## Statistical analyses

Statistical analysis title	Placebo versus PF-06700841 15 mg
Comparison groups	Placebo v PF-06700841 15 mg

Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.595 <sup>[4]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.1
upper limit	14.9

Notes:

[4] - One sided p-value.

<b>Statistical analysis title</b>	Placebo versus PF-06700841 30 mg
Comparison groups	Placebo v PF-06700841 30 mg
Number of subjects included in analysis	195
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.1125 <sup>[5]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	8.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	22.6

Notes:

[5] - One sided p-value.

<b>Statistical analysis title</b>	Placebo versus PF-06700841 45 mg
Comparison groups	Placebo v PF-06700841 45 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0891 <sup>[6]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	9.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	23.6

Notes:

[6] - One sided p-value.

---

## Secondary: Percentage of Participants Achieving a Reduction in Prednisone (or

---

**Equivalent) Dose to  $\leq 7.5$  mg/day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone  $>7.5$  mg/day (or Equivalent) at Baseline**

---

End point title	Percentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to $\leq 7.5$ mg/day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone $>7.5$ mg/day (or Equivalent) at Baseline
-----------------	--

End point description:

In this outcome measure data is reported for participants who achieved a reduction in prednisone (or equivalent) dose to  $\leq 7.5$  mg/day and sustained for 12 Weeks prior at Week 52 and they also sustained this dose reduction for 12 weeks prior to Week 52 (Week 40 to Week 52). FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Number of participants in FAS with baseline Prednisone or equivalent  $>7.5$  mg/day were analyzed. Here, "Number of Subjects Analyzed" signifies participants at Week 52 with NRI applied.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 52 for achieving reduction in dose along with Week 42 to Week 52 for sustained dosing

---

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	33	46	43
Units: Percentage of participants				
number (confidence interval 95%)	26.4 (13.6 to 39.2)	36.4 (18.4 to 54.3)	37.0 (21.9 to 52.0)	41.9 (26.0 to 57.8)

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52**

---

End point title	Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52
-----------------	--

End point description:

LLDAS was defined as SLE disease activity index (SLEDAI-2k  $\leq 4$ , with no activity in major organ systems [renal, central nervous system, cardiopulmonary, vasculitis, fever]) and no haemolytic anaemia or gastrointestinal activity; no new lupus disease activity compared with the previous assessment; a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI PhGA (scale 0-3; higher scores = higher severity)  $\leq 1$ ; a current prednisolone (or equivalent) dose  $\leq 7.5$  milligram per day (mg/daily); and well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Data from participants from few sites were excluded from FAS. Here "Number of Subjects Analyzed" signifies participants at Week 52 with NRI applied.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 52

---

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	93	47	97	88
Units: Percentage of participants				
number (confidence interval 95%)	22.6 (13.5 to 31.6)	21.3 (8.5 to 34.0)	35.1 (25.0 to 45.1)	34.1 (23.6 to 44.6)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to $\leq 7.5$ mg/day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone $>7.5$ mg/day (or Equivalent) at Baseline

End point title	Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to $\leq 7.5$ mg/day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone $>7.5$ mg/day (or Equivalent) at Baseline
End point description:	In this outcome measure data is reported for participants who achieved a reduction a SRI-4 response with prednisone dose reduced to $\leq 7.5$ mg/day and sustained for 12 weeks at Week 52. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Number of participants in FAS with baseline Prednisone or equivalent $>7.5$ mg/day were analyzed. Here, "Number of Subjects Analyzed" signifies participants at Week 52 with NRI applied.
End point type	Secondary
End point timeframe:	12 Weeks prior at Week 52 (Week 40 to Week 52)

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	33	46	43
Units: Percentage of participants				
number (confidence interval 95%)	20.8 (8.9 to 32.6)	30.3 (13.1 to 47.5)	32.6 (18.0 to 47.2)	32.6 (17.4 to 47.7)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants With $\geq 50\%$ Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score $\geq 10$

End point title	Percentage of Participants With $\geq 50\%$ Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score $\geq 10$
-----------------	--



---

**End point description:**

CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70). FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Number of participants in FAS with baseline CLASI-A score  $\geq 10$  were analyzed. Here, "Number of Subjects Analyzed" signifies participants at Week 52 with NRI applied.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Week 52

---

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	12	27	16
Units: Percentage of participants				
number (confidence interval 95%)	73.9 (53.8 to 94.0)	58.3 (26.3 to 90.4)	77.8 (60.2 to 95.3)	56.3 (28.8 to 83.7)

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52**

---

---

End point title	Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52
-----------------	---

---

End point description:

The  
FACIT-F

Scale is a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable with observed data at Week 52.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Baseline, Week 52

---

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	36	75	64
Units: Units on a scale				
least squares mean (confidence interval 95%)	4.6 (2.5 to 6.6)	7.4 (4.5 to 10.2)	5.8 (3.8 to 7.8)	7.6 (5.5 to 9.7)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52

End point title	Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52
-----------------	--

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others; measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Physical health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	36	75	64
Units: Units on a scale				
least squares mean (confidence interval 95%)	11.585 (7.475 to 15.695)	10.892 (5.241 to 16.544)	12.371 (8.464 to 16.278)	14.875 (10.748 to 19.002)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52

End point title	Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52
-----------------	---

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE

as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Emotional health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
End point timeframe:	
Baseline, Week 52	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	36	75	64
Units: Units on a scale				
least squares mean (confidence interval 95%)	8.113 (4.132 to 12.093)	10.469 (4.968 to 15.969)	7.547 (3.749 to 11.346)	11.823 (7.806 to 15.840)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Body Image Domain Scores of LupusQoL at Week 52

End point title	Change From Baseline in Body Image Domain Scores of LupusQoL at Week 52
-----------------	---

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Body image domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
End point timeframe:	
Baseline, Week 52	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	32	66	50
Units: Units on a scale				
least squares mean (confidence interval 95%)	9.207 (4.352 to 14.062)	10.935 (4.070 to 17.799)	8.169 (3.448 to 12.890)	15.599 (10.355 to 20.843)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Pain Domain Scores of LupusQoL at Week 52

End point title	Change From Baseline in Pain Domain Scores of LupusQoL at Week 52
-----------------	---

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Pain domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	36	75	64
Units: Units on a scale				
least squares mean (confidence interval 95%)	15.065 (10.470 to 19.659)	15.480 (9.132 to 21.828)	16.855 (12.488 to 21.223)	24.418 (19.790 to 29.047)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 52

End point title	Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 52
-----------------	--

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Fatigue domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all

participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
End point timeframe:	
Baseline, Week 52	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	36	75	64
Units: Units on a scale				
least squares mean (confidence interval 95%)	10.317 (5.951 to 14.683)	11.893 (5.892 to 17.894)	11.701 (7.550 to 15.853)	16.443 (12.036 to 20.850)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Planning Domain Scores of LupusQoL at Week 52

End point title	Change From Baseline in Planning Domain Scores of LupusQoL at Week 52
-----------------	---

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Planning domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
End point timeframe:	
Baseline, Week 52	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	36	75	64
Units: Units on a scale				
least squares mean (confidence interval 95%)	14.168 (9.423 to 18.912)	12.013 (5.487 to 18.538)	10.335 (5.826 to 14.843)	20.310 (15.523 to 25.097)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52

End point title	Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52
-----------------	--

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Intimate relationship domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	25	59	42
Units: Units on a scale				
least squares mean (confidence interval 95%)	12.430 (6.842 to 18.019)	12.625 (4.112 to 21.139)	6.494 (0.960 to 12.027)	15.363 (9.078 to 21.647)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52

End point title	Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52
-----------------	---

End point description:

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Burden to others domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life. FAS included all

participants randomly assigned to study intervention and have received at least 1 dose of study intervention. Here, "Number of Subjects Analyzed" signifies participants evaluable for this outcome measure with observed data at the specified visit.

End point type	Secondary
End point timeframe:	
Baseline, Week 52	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	36	75	64
Units: Units on a scale				
least squares mean (confidence interval 95%)	12.535 (7.227 to 17.842)	17.739 (10.412 to 25.065)	11.560 (6.500 to 16.621)	18.878 (13.523 to 24.233)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Incidence Rate of Severe Flare Event

End point title	Incidence Rate of Severe Flare Event
End point description:	
Incidence rate was defined as the number of participants with events per 100 participant-years. FAS included all participants randomly assigned to study intervention and have received at least 1 dose of study intervention.	
End point type	Secondary
End point timeframe:	
Week 52	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	96	47	100	97
Units: Participants per 100 participant-years				
number (confidence interval 95%)	8.32 (3.35 to 17.15)	6.92 (1.43 to 20.23)	3.24 (0.67 to 9.46)	6.95 (2.55 to 15.13)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Treatment-Emergent Adverse Events (AE)

End point title	Number of Participants With Treatment-Emergent Adverse Events (AE)
End point description: An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are events from first dose of study intervention to 4 weeks after last dose of study intervention that were absent before treatment or that worsened relative to pre-treatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.	
End point type	Secondary
End point timeframe: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	50	101	99
Units: Participants	80	38	88	83

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Serious Adverse Events (SAEs)

End point title	Number of Participants With Serious Adverse Events (SAEs)
End point description: An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.	
End point type	Secondary
End point timeframe: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	50	101	99
Units: Participants	8	4	8	9



## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Adverse Events Leading to Discontinuation From Study

End point title	Number of Participants With Adverse Events Leading to Discontinuation From Study
-----------------	--

End point description:

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. In this endpoint, participants with adverse events leading to discontinuation from study were reported. Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	50	101	99
Units: Participants	6	2	1	3

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

End point title	Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
-----------------	--

End point description:

Clinical significance in ECG abnormalities was judged by investigator. Safety analysis set (SAS) included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	50	101	99
Units: Participants	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Clinically Significant Vital Signs Abnormalities

End point title	Number of Participants With Clinically Significant Vital Signs Abnormalities
End point description: Vital signs included blood pressure, pulse rate, respiratory rate, and temperature. Clinical significance in vital signs abnormalities was judged by investigator. Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.	
End point type	Secondary
End point timeframe: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)	

End point values	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	50	101	99
Units: Participants	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Laboratory Test Abnormalities

End point title	Number of Participants With Laboratory Test Abnormalities
End point description: Hematology (Hemoglobin[hgb],hematocrit,erythrocytes[ery]:<0.8*lower limit of normal[LLN];reticulocytes,reticulocytes/ery:<0.5*LLN,>1.5*upper LN[ULN];ery mean corpuscular volume[EMC], EMC hgb:<0.9*LLN,>1.5*ULN;EMC hgb concentration:<0.9*LLN;platelet:<0.5*LLN;leukocytes[leu]:<0.6*LLN,>1.5*ULN;lymphocytes, lymphocytes/leu, neutrophils, neutrophils/leu:<0.8* LLN,>1.2*ULN;basophils, basophils/leu, eosinophils, eosinophils/leu, monocytes, monocytes/leu:>1.2*ULN;activated partial thromboplastin time[PTT], PTT, prothrombin time:>1.1*ULN);Clinical chemistry(Total/direct/indirect bilirubin, glucose-fasting:>1.5*ULN; aspartate aminotransferase[AT], alanine AT:>3.0*ULN; protein, albumin, HDL cholesterol:<0.8*LLN;urea nitrogen, creatinine, triglyceride, cholesterol:>1.3*ULN;urate,LDL cholesterol:>1.2*ULN;potassium:<0.9*LLN,>1.1*ULN;calcium, bicarbonate:<0.9*LLN;creatinine kinase:>2.0*ULN);Urinalysis (pH<4.5;glucose, protein, hgb, ketones, nitrite, leu esterase,	
End point type	Secondary

---

End point timeframe:

Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

---

<b>End point values</b>	Placebo	PF-06700841 15 mg	PF-06700841 30 mg	PF-06700841 45 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	50	101	99
Units: Participants	96	48	99	97

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Day 1 of dosing up to 4 weeks after last dose of study drug (maximum up to 56 weeks)

Adverse event reporting additional description:

Same event may appear as AE and SAE, what is presented are distinct events. Event may be categorised as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both serious and non-serious event during study.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants were randomized to receive placebo matched to PF-06700841 QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 30 mg
-----------------------	-------------------

Reporting group description:

Participants were randomized to receive PF-06700841 30 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 45 mg
-----------------------	-------------------

Reporting group description:

Participants were randomized to receive PF-06700841 45 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 15 mg
-----------------------	-------------------

Reporting group description:

Participants were randomized to receive PF-06700841 15 mg tablets orally QD for 52 weeks. Participants were followed up for 4 weeks after last dose.

Serious adverse events	Placebo	PF-06700841 30 mg	PF-06700841 45 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 100 (8.00%)	8 / 101 (7.92%)	9 / 99 (9.09%)
number of deaths (all causes)	0	1	1
number of deaths resulting from adverse events	0	1	1
Investigations			
Transaminases increased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive breast carcinoma			

subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cutaneous T-cell lymphoma			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nervous system disorders			
Lupus encephalitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic stroke			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intestinal strangulation			

subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Lupus pleurisy			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Ureterolithiasis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus nephritis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Systemic lupus erythematosus			

subjects affected / exposed	2 / 100 (2.00%)	1 / 101 (0.99%)	2 / 99 (2.02%)
occurrences causally related to treatment / all	1 / 2	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Upper respiratory tract infection			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	0 / 99 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			

subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	1 / 99 (1.01%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	PF-06700841 15 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 50 (8.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Investigations			
Transaminases increased			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive breast carcinoma			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cutaneous T-cell lymphoma			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Lupus encephalitis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thalamic stroke			



subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Intestinal strangulation			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhoids			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Lupus pleurisy			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Ureterolithiasis			

subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal colic			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lupus nephritis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Systemic lupus erythematosus			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COVID-19			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Pneumonia			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periorbital cellulitis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
COVID-19 pneumonia			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	PF-06700841 30 mg	PF-06700841 45 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	47 / 100 (47.00%)	53 / 101 (52.48%)	47 / 99 (47.47%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	4 / 99 (4.04%)
occurrences (all)	1	1	5
Nervous system disorders			
Headache			
subjects affected / exposed	5 / 100 (5.00%)	17 / 101 (16.83%)	9 / 99 (9.09%)
occurrences (all)	6	20	9
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 100 (0.00%)	6 / 101 (5.94%)	2 / 99 (2.02%)
occurrences (all)	0	6	2
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	5 / 100 (5.00%)	7 / 101 (6.93%)	6 / 99 (6.06%)
occurrences (all)	5	11	6
Nausea			
subjects affected / exposed	5 / 100 (5.00%)	3 / 101 (2.97%)	7 / 99 (7.07%)
occurrences (all)	5	3	9
Vomiting			
subjects affected / exposed	1 / 100 (1.00%)	4 / 101 (3.96%)	4 / 99 (4.04%)
occurrences (all)	1	4	4
Infections and infestations			
Cystitis			
subjects affected / exposed	3 / 100 (3.00%)	2 / 101 (1.98%)	2 / 99 (2.02%)
occurrences (all)	3	2	3
Nasopharyngitis			
subjects affected / exposed	7 / 100 (7.00%)	6 / 101 (5.94%)	8 / 99 (8.08%)
occurrences (all)	10	8	9
Oral candidiasis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 101 (0.00%)	6 / 99 (6.06%)
occurrences (all)	0	0	7
Upper respiratory tract infection			
subjects affected / exposed	7 / 100 (7.00%)	11 / 101 (10.89%)	8 / 99 (8.08%)
occurrences (all)	7	12	11
Urinary tract infection			
subjects affected / exposed	11 / 100 (11.00%)	10 / 101 (9.90%)	11 / 99 (11.11%)
occurrences (all)	13	11	12
COVID-19			
subjects affected / exposed	17 / 100 (17.00%)	11 / 101 (10.89%)	10 / 99 (10.10%)
occurrences (all)	17	11	10

<b>Non-serious adverse events</b>	PF-06700841 15 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 50 (38.00%)		
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences (all)	3		
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 5		
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)  Vomiting subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1  4 / 50 (8.00%) 4  3 / 50 (6.00%) 3		
Infections and infestations Cystitis subjects affected / exposed occurrences (all)  Nasopharyngitis subjects affected / exposed occurrences (all)  Oral candidiasis subjects affected / exposed occurrences (all)  Upper respiratory tract infection subjects affected / exposed occurrences (all)  Urinary tract infection subjects affected / exposed occurrences (all)  COVID-19 subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 8  5 / 50 (10.00%) 5  0 / 50 (0.00%) 0  1 / 50 (2.00%) 1  1 / 50 (2.00%) 2  9 / 50 (18.00%) 10		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 March 2021	The following modifications were made to PA4 as a result of the updated PF-06700841 Investigational Brochure (IB). The following changes were added and/or modified to the overview of the MoA and the safety profile of the product: Section 2.2.2. Clinical Overview Added study C2501007, an ongoing study in hidradenitis suppurativa. Updated to include additional guidance to the sites to encourage randomized participants to remain in the study at least through to the end of the double-blind period to complete safety and efficacy assessments.
28 September 2021	The overall rationale for B7931028 protocol amendment 6 is to address the Quantiferon gold test results which are not negative. The amendment will allow specific safety monitoring to be put into place to allow participants with latent TB (not active TB) to be eligible for the B7931028 study provided the protocol criteria can be met. China is having the biggest impact on enrolling participants into the study because of this eligibility criteria; however, once the next global protocol amendment is required, this language will be added as well.
06 June 2022	The overall rationale for B7931028 Protocol Amendment 7 is to decrease the sample size for the study from 448 participants to 350 participants, and to allow eligibility of participants with latent TB (positive quantiferon gold tests) who agree to receiving treatment with INH and Vitamin B6. This amendment also included the administrative changes made in Protocol Amendment 5 (requested during the EU Voluntary Harmonization Procedure (VHP) review of Amendment 4, countries submitting their initial clinical trial application with Amendment 5 (Italy and Argentina), and to any country requiring new protocol amendments to be submitted (Taiwan); and Protocol Amendment 6 (China only amendment) to be globally implemented. Furthermore, this change will allow specific safety monitoring to be put into place to allow participants with latent TB (not active TB) to be eligible for the study provided the protocol inclusion/exclusion criteria can be met.
15 June 2023	The driver for B7931028 Protocol Amendment 8 is to modify the key secondary endpoint of 'time to first severe SLE flare' and replace it with an exploratory endpoint of 'BICLA response at Week 52'. 'Time to first severe SLE flare' will remain as a secondary endpoint, just not the 'key' secondary endpoint and the data will be summarized as a secondary endpoint. The estimands for the associated endpoints have been updated to reflect these changes. E2, has been updated to align with the revised 'Key' secondary endpoint of 'BICLA response at Week 52' as was E7, the estimand for 'time to first severe SLE flare'.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

For the PF-06700841 30 mg, there was a total of 1 death which was reported in both on-treatment and follow-up phases in subject disposition section.

Notes: